Singapore, March 25 -- The Health Sciences Authority received information related to the study titled 'A Phase 2 Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study to Evaluate the Efficacy and Safety of MK-2214 in Participants with Early Alzheimer's Disease'. The following are the other relevant details related to the trial:
Therapeutic Area: Neurology
Trial Centre(s):
National Neuroscience Institute
Tan Tock Seng Hospital
Trial Status: Not Yet Recruiting
Principal Investigator(s):
Dr Ng Kok Pin
Dr Nagaendran Kandiah
Published by HT Digital Content Services with permission from Health Daily Digest....